ALPINE IMMUNE SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.56 USD | -0.09% |
|
+0.02% | +238.72% |
| Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
| Apr. 16 | TD Cowen Downgrades Alpine Immune Sciences to Hold From Buy | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 71.38 | 299.9 | 404.7 | 337.5 | 1,106 | 4,235 | - | - |
| Enterprise Value (EV) 1 | 71.38 | 299.9 | 404.7 | 114.1 | 778.1 | 3,931 | 4,028 | 3,960 |
| P/E ratio | -1.68 x | -9.4 x | -6.99 x | -4.25 x | -29.8 x | -39.2 x | -35.2 x | -27.5 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 41 x | 32.1 x | 17.3 x | 11.2 x | 18.8 x | 262 x | 225 x | 490 x |
| EV / Revenue | 41 x | 32.1 x | 17.3 x | 3.79 x | 13.2 x | 243 x | 214 x | 458 x |
| EV / EBITDA | - | - | -8.22 x | -1.96 x | -17.8 x | -32.8 x | -27.6 x | -24.3 x |
| EV / FCF | - | - | - | - | - | -40.8 x | -28.7 x | -22.9 x |
| FCF Yield | - | - | - | - | - | -2.45% | -3.48% | -4.37% |
| Price to Book | - | - | - | 1.88 x | - | 14.6 x | 27.4 x | 25.2 x |
| Nbr of stocks (in thousands) | 18,588 | 23,803 | 29,220 | 45,914 | 58,002 | 65,603 | - | - |
| Reference price 2 | 3.840 | 12.60 | 13.85 | 7.350 | 19.06 | 64.56 | 64.56 | 64.56 |
| Announcement Date | 3/30/20 | 3/18/21 | 3/17/22 | 3/23/23 | 3/18/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.74 | 9.335 | 23.44 | 30.06 | 58.88 | 16.15 | 18.79 | 8.647 |
| EBITDA 1 | - | - | -49.24 | -58.25 | -43.67 | -119.7 | -145.8 | -163.2 |
| EBIT 1 | -43.57 | -28.75 | -49.86 | -58.15 | -44.25 | -108.8 | -126.6 | -155.6 |
| Operating Margin | -2,504.25% | -307.97% | -212.68% | -193.41% | -75.16% | -673.84% | -673.91% | -1,799.15% |
| Earnings before Tax (EBT) 1 | -41.85 | -27.95 | -50.42 | -55.43 | -32.08 | -100.8 | -118.5 | -149.9 |
| Net income 1 | -41.85 | -27.94 | -50.33 | -57.76 | -32.18 | -100.6 | -112.8 | -149.8 |
| Net margin | -2,405.29% | -299.3% | -214.7% | -192.13% | -54.66% | -622.64% | -600.55% | -1,732.13% |
| EPS 2 | -2.280 | -1.340 | -1.980 | -1.730 | -0.6400 | -1.647 | -1.836 | -2.346 |
| Free Cash Flow 1 | - | - | - | - | - | -96.45 | -140.3 | -172.9 |
| FCF margin | - | - | - | - | - | -597.08% | -746.83% | -1,999.12% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/18/21 | 3/17/22 | 3/23/23 | 3/18/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8.516 | 4.53 | 13.63 | 5.292 | 8.367 | 2.776 | 9.387 | 8.593 | 10.04 | 30.85 | 3.516 | 3.489 | - | 3.502 | 5.223 | - |
| EBITDA 1 | -13.11 | -15.24 | -7.309 | -16.33 | -13.68 | - | -15.45 | -15.51 | -14.4 | 1.695 | -30.3 | -31.6 | - | -34 | -36.6 | - |
| EBIT 1 | -13.26 | -15.38 | -7.457 | -16.49 | -13.83 | -20.37 | -15.59 | -15.66 | -14.55 | 1.547 | -24.94 | -25.41 | - | -27.31 | -27.29 | -32.56 |
| Operating Margin | -155.74% | -339.43% | -54.71% | -311.58% | -165.32% | -733.75% | -166.1% | -182.18% | -144.88% | 5.01% | -709.45% | -728.22% | - | -779.67% | -522.42% | - |
| Earnings before Tax (EBT) 1 | -13.41 | -15.46 | -7.523 | -16.32 | -13.27 | -18.32 | -13.27 | -13.16 | -11.72 | 6.063 | -24.34 | -25.01 | - | -26.99 | -25.09 | - |
| Net income 1 | -13.49 | -15.17 | -7.527 | -18.1 | -13.27 | -18.86 | -13.27 | -13.16 | -11.72 | 5.96 | -23.95 | -24.84 | - | -26.78 | -25.7 | - |
| Net margin | -158.45% | -334.81% | -55.23% | -341.99% | -158.64% | -679.54% | -141.32% | -153.1% | -116.72% | 19.32% | -681.17% | -711.95% | - | -764.59% | -491.94% | - |
| EPS 2 | -0.5500 | -0.5200 | -0.2500 | -0.6000 | -0.4200 | -0.4100 | -0.2800 | -0.2700 | -0.2400 | 0.1500 | -0.3983 | -0.4067 | - | -0.4417 | -0.4050 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/17/22 | 5/12/22 | 8/11/22 | 11/14/22 | 3/23/23 | 5/11/23 | 8/14/23 | 11/14/23 | 3/18/24 | - | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 223 | 327 | 304 | 208 | 275 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | - | -96.5 | -140 | -173 |
| ROE (net income / shareholders' equity) | - | - | - | -38.5% | -12.7% | -34% | -69.3% | -106% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | 3.900 | - | 4.430 | 2.360 | 2.560 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | - | - | 2.25 | 2 | 2.42 |
| Capex / Sales | - | - | - | - | - | 13.93% | 10.65% | 27.95% |
| Announcement Date | 3/30/20 | 3/18/21 | 3/17/22 | 3/23/23 | 3/18/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
64.56
USD
Average target price
62
USD
Spread / Average Target
-3.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +238.72% | 4.24B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ALPN Stock
- Financials Alpine Immune Sciences, Inc.
